NCT04068831View on ClinicalTrials.gov

Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 22, 2019

Primary Completion Date

December 6, 2023

Study Completion Date

December 6, 2023

Conditions
Metastatic Renal Cell CarcinomaFumarate Hydratase Deficient Renal Cell CarcinomaSuccinate Dehydrogenase Deficient Renal Cell Carcinoma
Interventions
DRUG

Talazoparib

1 mg talazoparib daily

DRUG

Avelumab

800 mg avelumab every 2 weeks

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT04068831 - Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter